سامية محمد مصطفى



شبكة المعلومات الحامعية

# بسم الله الرحمن الرحيم



-Caro-

سامية محمد مصطفي



شبكة العلومات الحامعية



شبكة المعلومات الجامعية التوثيق الالكتروني والميكروفيلم





سامية محمد مصطفي

شبكة المعلومات الجامعية

## جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

## قسو

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة يعيدا عن الغيار



سامية محمد مصطفي



شبكة المعلومات الجامعية



المسلمة عين شعور المسلمة عين شعور المسلمة عين شعور المسلمة عين شعور المسلمة ا

سامية محمد مصطفى

شبكة المعلومات الحامعية



بالرسالة صفحات لم ترد بالأصل





#### STUDIES OF TUMOUR MARKERS IN BLOOD AND TISSUE OF COLORECTAL CARCINOMA

#### **THESIS**

Submitted in partial fulfillment for the degree of M.D. (General Surgery)

By
Mahmoud Galal Abdel Ghaffar
M.B.B.Ch; M.S. General Surgery

Faculty of Medicine - Assiut University

Supervised by **Prof. Dr. Mohamed A. El-Sebaity** 

Professor of General Surgery and Head of Departments of Surgery

Prof. Dr. Farouk A. Mourad Professor of General Surgery


**Prof. Dr. Osama Bakr Sadik**Professor of Clinical Pathology

**Dr. Nemat Alla Abdel Fattah**Assistant Professor of Pathology

**Faculty of Medicine - Assiut University** 

181.4

1991



( سـورة يوسف ، آية ٧٦ ك )

# TO MY FATHER TO MY FATHER IN LAW

#### ACKNOWLEDGMENT

I would like to express my sincere gratitude to my Prof. Dr. Mohammed Ali El-Sebaity, Professor of Surgery and Head of General Surgery Department, Faculty of Medicine, Assiut University for his instructive supervision, and scientific planning of this work.

Cordial thanks to Prof. Dr. Farouk Mourad, Professor of General Surgery, for his valuable guidance and most appreciated encouragement. The credit of bringing this work to light goes to him.

I am deeply indebted to Prof. Dr. Osama Bakr Sadik, Professor of Clinical Pathology, Faculty of Medicine, Assiut University, for his continuous indispensable advice, without which this thesis would not have been delivered in this form.

I wish to express my everlasting gratitude and great appreciation to Dr. Nemet Allah Abdel Fatah, Assistant Prof. of Pathology, Faculty of Medicine, Assist University for promoting this work and for her valuable advises.

Sincere thanks to Prof. Dr. Marscelle N. Guirguis, Prof. of Pathology, Faculty of Medicine, Assiut University for provision of facilities and generous help.

Thanks also to my colleagues in General Surgery Department, Departments of Clinical Pathology and Pathology for their kind help.

Thanks to Dr. Hamdy Abd El-minaim, The Lacturre of Surgery, Faculty of Medsin, Menia University for his great help.

Thanks to Dr. Salah Ebrahim, The Lacturre Dep of Surgery, Assiut University, for his help.

Thanks to Dr. Nivin Abd El-minaim, Lacture of Clincal Pathol. Assiut University, for her great help.

#### **ABBREVIATIONS**

AFP: Alpha feto protein

CEA: Carcinoembryonic antigen

LDH: Lactate dehydrogenase

AP: Alkaline phosphatase

GR: Glutathione reductase

SGOT: Serum glutamic oxaloacetic transaminase

SGPT: Serum glutamic pyruvate transaminase

PBS: Phosphate buffered solution

#### **CONTENTS**

_	Themselvers	
	Introduction	• ;
_	Aim of work	. (
-	Review of literature	. :
	- Surgical anatomy of colo-rectal cancer	. 7
	- Histology of the large bowel	. 18
	- Aetiology of colorectal cancer	. 21
	- Clinical features of colorectal cancer	. 26
	- Biology of large bowel cancer	. 44
	- Pathology of colo-rectal carcinoma	. 49
	- Immunohistochemical determination of tissue	
	carcinoembryonic antigen (CEA)	. 73
	- Serum carcinoembryonic antigen	. 86
	- Alpha fetoprotein (AFP)	112
	- Serum enzymes in colo-rectal cancer	118
_	Material and methods	128
_	Results	177
	- Clinical results	177
	- Histochemical results	186
	- Serum carcinoembryonic antigen (CEA)	223
	- Results of alpha feto-protein (AFP)	
-	Discussion	248
-	Summary and conclusion	272
-	References	276

## INTRODUCTION

#### INTRODUCTION

Colo-rectal carcinoma looks quite common in comparison to the cancer of other organs in our locality and it is definitely responsible for a percentage of cancer deaths in general.

The reports of clinico- pathological studies of colorectal cancer are so frequent in different areas all over the world. During the last few decades the biochemical study have been established, and the determination of tumour marker become one from the other investigatory schedule which may be of great help in early diagnosis, prognosis, or addition of the tumour marker to other investigation may strengthen the diagnosis.

Tumour markers are substances make by tumours, or are at least closely associated with the presence of tumours, that can aid in the diagnosis of cancer and in the assessment of tumour burden.

Measurement of tumour markers has important implication for the diagnosis and management of cancer and also for basic understanding of the biology of human tumours.

A variety of substance may be useful as tumour markers. Some are normally present in the tissues of the fetus then either disappear or are greatly reduced in amount by the end of gestation or shortly after birth. These have been termed oncofetal antigens or embryonic antigens. tumour markers may be normally produced by the placenta. Some tumour markers may be characteristic of cancers of a particular tissue or organ and some may be present in some normal adult tissues, but may be functionally quantitatively altered in tumours or may be released in higher concentrations into the circulation of cancer patients.

Antigens of oncogenic viruses, or at least antigens cross-reactive with viral proteins, may also be detectable in some human tumours. Most tumour markers are characterized only by their immunologic properties, but some have functional activities or are variants of normal functional products. These include hormones, enzymes and metal-binding and secretory proteins.

In addition to detection of tumour markers by their antigenic specificities, assays have been developed recently for the general detection of circulating antigen-antibody complexes, and a considerable number of cancer patients have